Significant Blood Pressure Reduction From St. Jude Medical (STJ)'s EnligHTN Renal Denervation Technology is Safe, Effective and Sustained at Six Months
11/5/2012 10:12:35 AM
ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that the company’s EnligHTN™ renal denervation system provided a safe, effective and sustained reduction in office and ambulatory blood pressure measurements at six months. The new data was released in the Clinical Science and Special Reports Session during the annual American Heart Association (AHA) meeting.
comments powered by